Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Mallinckrodt

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

DESONATE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Desonate patents expire, and when can generic versions of Desonate launch?

Desonate is a drug marketed by Leo Pharma As and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-four patent family members in twenty-two countries.

The generic ingredient in DESONATE is desonide. There are thirty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desonide profile page.

US ANDA Litigation and Generic Entry Outlook for Desonate

A generic version of DESONATE was approved as desonide by TARO on January 26th, 2020.

  Start Trial

Drug patent expirations by year for DESONATE
Drug Prices for DESONATE

See drug prices for DESONATE

Drug Sales Revenue Trends for DESONATE

See drug sales revenues for DESONATE

Recent Clinical Trials for DESONATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest UniversityPhase 4

See all DESONATE clinical trials

Recent Litigation for DESONATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Bayer Healthcare Pharmaceuticals, Inc. v. River's Edge Pharmaceuticals, LLC2011-05-19
Medicis Pharmaceutical Corporation v. Actavis Mid Atlantic LLC2011-05-11
Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC2010-08-19

See all DESONATE litigation

Pharmacology for DESONATE
Synonyms for DESONATE
(11ss,16alpha)-11,21-Dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0;{2,9}.0;{4,8}.0;{13,18}]icosa-14,17-dien-16-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
16-alpha-Hydroxyprednisole-16,17-acetonide
16?,17-[1-Methylethylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-hydroxyprednisole-16,17-acetonide
16alpha-hydroxyprednisolone-16alpha,17-acetonide
16alpha,17-[1-Methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione (Desonide)
16alpha,17alpha-isopropylidenedioxyprednisolone
638-94-8
638D948
AB01274712_02
AB01274712-01
AB2000229
Apolar
AS-13892
BCP04201
BRD-K21528677-001-03-6
C-22009
CAS-638-94-8
CC-26356
CCG-221279
CHEBI:204734
CHEMBL1201109
CS-2228
D 2083
D-2083
D03696
D2083
DB01260
desfluorotriamcinolone acetonide
Desilux
Desonida
Desonida [INN-Spanish]
DESONIDE
Desonide (USAN/INN)
Desonide [USAN:INN:BAN]
Desonidum
Desonidum [INN-Latin]
DesOwen
Desowen (TN)
DSSTox_CID_26756
DSSTox_GSID_46756
DSSTox_RID_81880
DTXSID7046756
EINECS 211-351-6
Flusemidon
GTPL7066
Hamiltoderm
HMS3715P20
HY-B0248
J280872D1O
K016
Locapred
Locapred;Topifug;Tridesilon
MolPort-003-987-087
NCGC00167983-01
NCGC00274065-01
Prednacinolone
Prednisolone-16,17-acetonide, 16-alpha-hydroxy-
Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
Prenacid
Q-101382
Reticus
s1701
SC-17104
SCHEMBL3631
Sterax
Steroderm
TL8004516
Topifug
Tox21_112603
Tox21_112603_1
Tridesilon
Tridesonit
UNII-J280872D1O
Verdeso
Verdeso (TN)
WBGKWQHBNHJJPZ-LECWWXJVSA-N
ZINC4212851
Zotinar
Paragraph IV (Patent) Challenges for DESONATE
Tradename Dosage Ingredient NDA Submissiondate
DESONATE GEL;TOPICAL desonide 021844 2010-12-01

US Patents and Regulatory Information for DESONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As DESONATE desonide GEL;TOPICAL 021844-001 Oct 20, 2006 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DESONATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 2013/044 Ireland   Start Trial PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
1304992 C01304992/01 Switzerland   Start Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1304992 PA2013025,C1304992 Lithuania   Start Trial PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992 PA2013025 Lithuania   Start Trial PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKinsey
Dow
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.